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Despite advances in detection and therapy, epithelial ovarian cancer (EOC) still represents the most lethal
gynecologic malignancy in women worldwide. The high mortality of EOC is mainly due to late-stage diagnosis for
more than 70% of patients. There is an urgent need to search for specific and sensitive biomarkers for early
diagnosis of EOC. Recently, the cumulative data indicated an essential role for microRNA (miRNA), a class of small
non-coding RNAs targeting multiple mRNAs and triggering translation repression and/or RNA degradation, in
ovarian caner carcinogenesis and progression. Here, we reviewed the published miRNA expression profiling studies
that compared the miRNA expression profiles between EOC tissues or cell lines and normal ovarian tissues or
benign ovarian tumor or human primary cultured ovarian surface epithelial cells. A miRNA ranking system that takes
the number of comparisons in agreement and direction of differential expression into the consideration was
devised and used. Finally, five promising differentially miRNAs (miR-200a, miR-100, miR-141, miR-200b, and miR-200c)
were reported with the consistent direction in four or more studies. MiR-200a, miR-200b, miR-200c, and miR-141,
all of them belong to miR-200 family, were reported with consistently up-regulated in at least 4 studies, whereas
miR-100 was reported with down-regulated in 4 studies. Furthermore, we validated these miRNAs in a clinical
setting using qRT-PCR and their dysregulations in EOC tissues confirmed the findings. Conclusively, the five most
consistently expressed miRNAs might provide some clues of the potential biomarkers in EOC. Further mechanistic
and precise validation studies are needed for their clinical significances and roles in the progression of EOC.
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Epithelial ovarian cancer (EOC, referred to as ovarian
cancer in this review) is the fifth leading cause of cancer
death in women and the most lethal gynecologic malig-
nancy in the world [1]. Despite recent advances in che-
motherapeutic treatments that have improved the initial
responses, the 5-year survival rate for women with ad-
vanced stage ovarian cancer is only about 30% after initial
diagnosis [2]. Pessimistically, more than 70% of EOC pa-
tients appeared the first specific symptoms and are diag-
nosed only during advanced disease stage [3]. Although
various screening methods or specific markers for early* Correspondence: lychenying2004@126.com
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reproduction in any medium, provided the ordetection of EOC are available, their diagnostic values are
limited due to lack of sensitivity, high costs and or incon-
venience. Thus, there is an urgent need to identify new
diagnostic and prognostic biomarkers for EOC.
MicroRNAs (miRNAs) are a class of small (19 to 25 nt),
non-coding, highly stable RNAs that regulate mRNA and
protein expression. Several studies have indicated that
miRNAs have been involved in regulating various bio-
logical processes, such as cellular differentiation, prolifera-
tion, angiogenesis, metabolism and cancer development
[4-6]. Microarray-based miRNA profiling assays attracted
more attention because they constitute the efficient meth-
odology to screen in parallel for the expression of hun-
dreds of miRNAs through extensive sample collections.
As we know, with the aim at identifying new biomarkers
of ovarian cancer, many investigators have carried out
miRNAs expression profiling studies in cell lines, tissue ortd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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identified to be differentially expressed and can be either
up- or down- regulated, depending on their target down-
stream genes, although only a small fraction of them may
actually be of clinical utility as diagnostic/prognostic
biomarkers or therapeutic targets.
However, there had been inconsistency or discrepancy
in the identified differentially expressed miRNAs among
the different profiling studies, which give rise to identify
the most consistently reported differentially expressed
miRNAs in multiple independent studies necessarily.
Although the identification of intersections of the cancer-
related genes based on a large number of gene profiling
studies has become increasingly popular, there has been
no study investigating the intersections of cancer-related
miRNAs based on a number of miRNA expression profil-
ing studies in ovarian cancer.
Thus, we summarized this systematic review to deter-
mine the differentially expressed up- and down- regulated
miRNAs that were consistently reported in different in-
dependent miRNA expression profiling studies in EOC.
Furthermore, the most consistently expressed miRNAs
were validated in a clinical setting.
Material and methods
Literatute selection
To identify all relevant literature, we searched PubMed
for ovarian cancer miRNA expression profiling studies
published between January 2002 and December 2012, by
means of the MeSH terms: ‘ovarian neoplasms’ and
‘microRNAs’ in combination with the keyword ‘profiling’
and ‘humans’. Eligible studies had to meet the following
criteria: ① they were miRNA expression profiling studies
in ovarian cancer patients or ovarian cancer cell lines;
② they used tissue samples obtained from surgically
removed EOC specimens or epithelial ovarian cancer
cell lines and benign ovarian tumor or normal ovarian
tissues or human primary cultured ovarian surface epi-
thelial cells for comparison; ③ use of miRNA microarray
methods; ④ reporting of cut-off criteria of differentially
expressed miRNAs; ⑤ validation method and validation
sample set reported; and⑥ they were published as full arti-
cles in English only. Therefore, the miRNA profiling studies
using the serum of ovarian cancer patients, or using differ-
ent miRNA technologies were excluded. Review articles
and studies comparing miRNA expression profiles in EOC
with cisplatin-sensitive and cisplatin-resistant or refractory
were also excluded.
Data abstraction
Two investigators (YC and LZ) independently evaluated
and extracted the data with the standard protocol and
with all the discrepancies resolved by a third investigator
(QH). From the full text and corresponding supplementinformation, the following eligibility items were collected
and recorded for each study: author, journal and year of
publication, location of study, selection and characteristics
of recruited ovarian cancer patients, platform of miRNA
expression profiling, author defined cut-off criteria of statis-
tically differentially expressed miRNAs, the list of up- and
down-regulated miRNA features, and the frequency of dif-
ferent miRNAs reported among these eligible literatures.
Ranking
Each of published miRNA expression profiling studies
comparing miRNA expression between EOC or ovarian
cancer cell lines and benign ovarian tumor or normal
ovarian tissues or human primary cultured ovarian surface
epithelial cells resulted in a list of differentially expressed
miRNAs. These miRNAs were ranked according to several
criteria, which were similar to those in Griffith’s [18] and
Chan’s [19] studies in the following order of importance:
① the miRNA was consistently reported as differentially
expressed; ② the consistently reported differentially
expressed miRNA was also in a consistent direction of
change; ③ the frequency of the miRNA was reported
in the miRNA ecpression profiling studies.
Validation of the most consistently differentially
expressed miRNAs using quantitative real-time PCR
To validate the microarray results, ten fresh EOC specimens
were collected from women during primary surgery and
prior to the initiation of adjuvant therapy at the Department
of Gynecologic Oncology, Tianjin Medical University Cancer
Institute and Hospital. Ten normal ovarian tissues were
obtained from women who underwent surgery for benign
or malignant gynecological diseases other than ovarian car-
cinoma at the same department. Total RNA was extracted
using the Qiagen RNeasy Kit (QIAGEN GmbH, Germany)
according to the manufacturer’s instructions. First-strand
complementary DNA (cDNA) was synthesized from 2 μg
of tatal RNA using an oligo-dT primer and superscript II
reverse transcriptase (Invitrogen). Then, quantification was
performed by real-time PCR, using SYBRRPremix Ex
Taq TM (TakaRa) for the most consistently differentially
expressed miRNAs. The primers for U6 were obtained
from TakaRa. PCR was performed in a real-time PCR
system (BIO-RAD) as follows: 95°C for 3 min followed
by 35 cycles of 95°C for 5 sec, 60°C for 20 sec and 72°C
for 30 sec and then 94°C for 1 min, 60°C for 1 min, with
addition of a cycle for every 0.5°C. Expression values
were normalized to those for U6. Relative fold changes of
miRNA expression were calculated by the ΔΔCT method,
and the values were expressed as 2-ΔΔCT.
Statistical analysis and ethics statement
Statistical analyses were performed by GraphPad Prism
Software (GraphPAD Prism Software, Version 5.01,
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defined as P<0.05. All human specimens were obtained
with the written informed consent of participants in
accordance with the requirements of the Research Ethics
Committee of Tianjin Medical University Cancer Institute
and Hospital, China.
Results
Independent studies for data extraction
In total, 80 studies were searched using PubMed. Following
the strict inclusion and exclusion criteria, only 8 independ-
ent studies were included in the systematic analysis. The
characteristics of these studies are listed in Table 1.
Differentially expressed miRNAs
A total of 185 differentially expressed miRNAs were
reported in the 8 miRNA expression profiling studies. The
chromosomal localizations, pre-miRNA lengths, mature
sequences, and the potential targets of the differentially
expressed miRNAs are listed in the Tables 2, 3, 4 and 5.
Consistently reported, inconsistently reported and most
consistently reported differentially expressed miRNAs
Among the 185 differentially expressed miRNAs reported
from eight studies, 17 miRNAs were reported in at least
three or more expression profiling studies; 6 (35.3%) with
a consistent direction and 11 (64.7%) with an inconsistent
direction among the studies (Table 2). MiR-200a and miR-
100 were reported in 6 studies; MiR-141 and miR-99a
were reported in 5 studies; MiR-200b and miR-200c were
reported in 4 studies and 11 miRNAs (miR-143, miR-145,
miR-214, miR-134, miR-154, miR-424, miR-29a, miR-21,
miR-10b, miR-26a, and let-7d) were reported in 3 studies.
Additionally, 10 miRNAs were reported with consistent
direction between two studies (Table 3) and 7 miRNAs
were reported with inconsistent direction between
two studies (Table 4). More importantly, 5 differentially
miRNAs (miR-200a, miR-100, miR-141, miR-200b, andTable 1 Eight microRNA expression profiling studies included
Reference Year Platform
Kim et al. [7] 2010 MiRNA microarray (human-miRNA-V1 bead
Zhang et al. [8] 2008 TaqMan miRNA Assay (PE Applied biosystems, Fo
Nam et al. [9] 2008 mirVana miRNA Probe Set (Ambion
Iorio et al. [10] 2007 MiRNA microarray (Ohio State comprehensiv
center, version 2.0)
Dahiya et al. [11] 2008 MiRCURYTM LNA miRNA Arrays (Exiqo
Yang et al. [12] 2008 Oligonucleotide arrays
Wyman et al. [13] 2009 454 Life sciences
Chao et al. [14] 2011 TaqMan miRNA Assay (PE Applied Biosystems, Fo
* The authors did not showed the total number of the differently expressed miRNA
for the follow-up experiments.miR-200c) were reported with the consistent direction
among four or more studies (Table 5).
Experimental validation of expression of the most
consistently differentially expressed miRNAs in patients
with EOC
To validate the expression of the five most consistently
reported miRNAs (miR-200a, miR-100, miR-141, miR-200b,
and miR-200c), that may be the candidate biomarkers for
EOC, the expression of these miRNAs between EOC and
normal ovarian tissues were compared using qRT-PCR
analysis. The preliminary results showed that the level
of miR-100 was decreased, whereas the levels of miR-200a,
miR-200b, miR-200c, and miR-141 were all increased in
the EOC tissues, compared to the normal ovarian tissues
(all of them P<0.001) (Figure. 1).
Discussion
The common drawback of miRNA expression profiling
studies is a lack of agreement among several studies.
With reference to previous studies, a logical solution to
the problem is to determine the agreement among the
miRNA expression profiling studies using different
platforms and observe which differentially expressed
miRNAs are consistently reported. Notably, cumulative
data had demonstrated that several consistently expressed
miRNAs, maybe as candidate biomarker, were showed in
some profiling studies of colorectal carcinoma [20] and
lung cancer [21], respectively.
However, the general and accurate study of consistent
miRNA expression in ovarian cancer versus normal ovary
or benign ovarian tumors profiles had not been reported
before. In this study, we observed that a total of 185 differ-
entially expressed miRNAs were reported in the 8 miRNA
expression profiling studies, but only 17 miRNAs were
reported in at least three or more expression profiling stud-
ies. Excitingly, among the 17 miRNAs, 5 promising differ-
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Mature sequence Potential target References
miR 200a 1p36.33 90 nt 54∣5′-UAACACUGUCUGGUAACGAUGU-3′∣75 ZEB1; ZEB2; CCNL2; [9-14]
miR 100 11q24.1 80 nt 13∣5′-AACCCGUAGAUCCGAACUUGUG-3′∣34 TARDBP; FRAP1 [8-13]
miR 141 12p13.31 95 nt 17∣5′-CAUCUUCCAGUACAGUGUUGGA-3′∣38 AP3S1; ZEB1 [9-11,13,14]
miR 99a 21q21.1 81 nt 13∣5′-AACCCGUAGAUCCGAUCUUGUG-3′∣34 TARDBP; FRAP1 [8-11,13]
miR 200b 1p36.33 95 nt 57∣5′-UAAUACUGCCUGGUAAUGAUGAC-3′∣34 ZEB1; ZEB2; TARDBP; [9,10,13,14]
miR 200c 12p13.31 68 nt 44∣5′-UAAUACUGCCGGGUAAUGAUGG-3′∣34 ZEB1; ZEB2; TARDBP; [9,10,13,14]
miR 143 5q32.33 106 nt 61∣5′-UGAGAUGAAGCACUGUAGCUCA-3′∣82 ENO1; KIF1B; K-Ras [9,10,13]
miR 145 5q32 88 nt 16∣5′-GUCCAGUUUUCCCAGGAAUCCCUU-3′∣39 RERE; CTNNBIP1; FSCN1 [8-10]
miR 214 1q23 110 nt 71∣5′-ACAGCAGGCACAGACAGGCAG-3′∣91 CCNL2; WDR8; WDR8 [9,10,12]
miR 134 q32.31 73 nt 8∣5′-UGUGACUGGUUGACCAGAGGGG-3′∣29 VEGFR; ABCC1 [9,10,12]
miR 154 14q32.31 84 nt 15∣5′-UAGGUUAUCCGUGUUGCCUUCG-3′∣36 FAM63B; GALNT7 [8,10,11]
miR 424 Xq26.3 98 nt 11∣5′-CAGCAGCAAUUCAUGUUUUGAA-3′∣32 FGF2 [8,11,14]
miR 29a 7q32.3 64 nt 42∣5′-UAGCACCAUCUGAAAUCGGUUA-3′∣63 C4orf32 [8,11,12]
miR 21 17q23.1 72 nt 8∣5′-UAGCUUAUCAGACUGAUGUUGA-3′∣29 CLCA3P; SATB1 [9,11,12]
miR 10b 2q31.1 110 nt 27∣5′-UACCCUGUAGAACCGAAUUUGU-3′∣34 CTNNBIP1; VPS13D [9,11,13]
miR 26a 3p22.2 or 12q14.1 77 nt or 84 nt 10∣5′-UUCAAGUAAUCCAGGAUAGGC-3′∣30 or
14∣5′-UUCAAGUAAUCCAGGAUAGGC-3′∣34
UBE4B [8,9,13]
Let 7d 9q22.32 87 nt 8∣5′-AGAGGUAGUAGGUUGCAUAGUU-3′∣29 HMGA2; C14orf28 [8,10,11]







Mature sequence Direction of
expression
Potential target Reference
miR 182 7q32.2 110 nt 23∣5′-UUUGGCAAUGGUAGAACUCACACU-3′∣46 ↑ NRCAM; RGS17 [8]
↑ [14]
miR 16 13q14.2 89 nt 14∣5′-UAGCAGCACGUAAAUAUUGGCG-3′∣35 ↑ UNC80; KIF21A [9]
↑ [13]
miR 29c 1q32.2 88 nt 54∣5′-UAGCACCAUUUGAAAUCGGUUA-3′∣75 ↑ COL3A1 [13]
↑ [11]
miR 224 Xq28 81 nt 8∣5′-CAAGUCACUAGUGGUUCCGUU-3′∣28 ↓ CDADC1; UBXN4 [8]
↓ [10]
miR 125b 11q24.1 88 nt 15∣5′-UCCCUGAGACCCUAACUUGUGA-3′∣36 ↓ CSNK2A1; FAM169B [9]
↓ [12]
miR 127 14q32.2 97 nt 23∣5′-CUGAAGCUCAGAGGGCUCUGAU-3′∣44 ↓ NEK1 [8]
↓ [10]
Let-7a 9q22.32 80 nt 6∣5′-UGAGGUAGUAGGUUGUAUAGUU-3′∣27 ↓ C14orf28; HMGA2 [12]
↓ [10]
Let-7c 21q21.1 84 nt 11∣5′-UGAGGUAGUAGGUUGUAUGGUU-3′∣32 ↓ C14orf28; HMGA2 [10]
↓ [12]
Let-7b 22q13.31 83 nt 6∣5′-UGAGGUAGUAGGUUGUGUGGUU −3′∣27 ↓ C14orf28; HMGA2 [9]
↓ [12]
miR 125a 19q13.41 86 nt 15∣5′-UCCCUGAGACCCUUUAACCUGUGA −3′∣38 ↓ CSNK2A1; ZNF543 [9]
↓ [10]
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Mature sequence Direction of expression Potential target Reference
miR 494 14q32.31 81 nt 48∣5′-UGAAACAUACACGGGAAACCUC-3′∣69 ↑ ARID4B; DZIP3 [11]
↓ [12]
miR 221 Xp11.3 110 nt 65∣5′-AGCUACAUUGUCUGCUGGGUUUC-3′∣87 ↑ LRRCC1; GABRA1 [11]
↓ [13]
miR 519a 19q13.42 87 nt 54∣5′-AAAGUGCAUCCUUUUAGAGUGU-3′∣75 ↑ FILIP1L [11]
↓ [7]
miR 335 7q32.2 94 nt 16∣5′-UCAAGAGCAAUAACGAAAAAUGU-3′∣38 ↑ SMARCA2; LMX1A [13]
↓ [11]
miR 126 9q34.3 85 nt 52∣5′-UCGUACCGUGAGUAAUAAUGCG-3′∣73 ↑ HOXA3; PPP3CB [13]
↓ [10]
miR 199a 19p13.2 71 nt 6∣5′-CCCAGUGUUCAGACUACCUGUUC-3′∣28 ↑ ZNF763 [12]
↓ [10]
miR 138 16q13 84 nt 10∣5′-AGCUGGUGUUGUGAAUCAGGCCG-3′∣32 ↑ PKP4; RIMS2 [14]
↓ [11]
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Figure 1 qRT-PCR analysis of miR-200a, miR-100, miR-141, miR-200b, and miR-200c expressions in the EOC and normal ovarian tissues.
The results showed that the level of miR-100 was decreased, whereas the levels of miR-200a, miR-200b, miR-200c, and miR-141 were all increased
in the EOC tissues, compared to the normal ovarian tissues (all of them P<0.001).
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in four or more studies. It is that MiR-100 was down-
regulated and the others all up-regulated in EOC tissues.
Then, in order to determine whether the above five
identified miRNAs had been previously validated to
have diagnostic or prognostic values as biomarkers in
EOC, a literature review and validation experiment were
performed. Gratifyingly, the data of using EOC and normal
ovarian specimens collected in our center was consistent
with the findings of profiling studies.
Particularly, all of them (miR-200a, miR-200b, miR-200c,
and miR-141), four up-regulated miRNAs of the five most
consistently expressed miRNA among the eight profiling
studies, belong to the miR-200 family. MiR-200a and miR-
200b are located on chromosome 1, while miR-200c and
miR-141 are on chromosome 12. The most prominent tar-
gets of the miR-200 family are two E-box binding transcrip-
tion factors, ZEB1 and ZEB2, keys regulators of a complex
network of transcriptional repressors regulating E-cadherin
expression and epithelial polarity. Consistent with this func-
tion, the miR-200 family was recently identified as a marker,as well as a powerful regulator of the epithelial-to-mesen-
chymal transition (EMT). Indeed, EMT played an import-
ant role in carcinogenesis and tumor progression, when
tumor cells undergo a change from a differentiated to a
dedifferentiated, more aggressive and invasive phenotype.
Furthermore, the increased expression of miR-200a might
underlie genomic amplification. Frequent chromosomal
gains in that region have been reported in ovarian carcin-
oma [22]. The inhibition of miR-200b increased the sensi-
tivity to gemcitabine in cholangiocarcinoma cell lines [23],
and thereby, increased expression of miR-200b may result
in poor response to antineoplastic drugs. Moreover, inhib-
ition of miR-141 using anti-miR-141 decreased cell growth
in choloangiocarcinoma cell lines [23]. Accordingly, miR-
200b and miR-141 could be a novel target for enhancing
chemosensitivity or inducing cell death in ovarian cancer.
Additionally, high expression of miR-200a was identified
to correlate with decreased progression-free survival and
overall survival for EOC patients significantly, even as
miR-200c [9,16]. As a result, miR-200 family might serve
as a molecular marker for the prediction of the prognosis
Chen et al. Cancer Cell International 2013, 13:86 Page 7 of 8
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EOC patients.
MiR-100, another important consistent expressed miRNA
in this study, may be as another candidate biomarker in
ovarian cancer, which has been reported to be down-
regulated in 5 profiling studies but up-regulated only in
one study. MiR-100 represses mTOR (mammalian target
of rapamycin) signaling and increases sensitivity to the
cancer drug everolimus (rapamycin analog RADOO1) in
cell lines derived from clear cell carcinomas [24]. mTOR
is a serine/threonine kinase and downstream effector of
the AKT signaling pathway, which has also been shown to
be a possible therapeutic target in both cisplatin-sensitive
and cisplatin-resistant clear cell ovarian carcinoma [24,25].
Additionally, miR-100 inhibited cell proliferation by
suppressing mTOR in esophageal squamous cell car-
cinoma (ESCC) cell lines and Low miR-100 expression
was associated with worse overall survival in ESCC patients
[26]. Recently, Peng et al. showed that miR-100 can sig-
nificantly inhibit growth of EOC cells by targeting PLK1
(Polo-like kinase-1) and more importantly, miR-100 may
be as an independent predictor for the prognosis evalu-
ation of ovarian cancer patients. Thus, they suggested the
miR-100/PLK1 signaling pathway may provide therapeutic
targets for human EOCs [17].
Conclusively, this systematic review and validation
experiment demonstrated four up-regulated miRNAs
(miR-200a, miR-200b, miR-200c and miR-141) and one
down-regulated miRNA (miR-100) are promising im-
portant candidate biomarkers for EOC. However, the
shortcomings of this study are review of profiling studies
with retrospective and limited profiles. Further clinical
and mechanistic studies focusing on these miRNA need
to be performed for their clinical significance and the
underlying roles in tumorigenesis of EOC.Competing interest
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